Elevated remnant cholesterol as a potential predictor for cardiovascular events in rheumatoid arthritis patients

被引:1
作者
Chang, Ching-Kun [1 ,2 ,3 ,4 ]
Li, Yi-Chen [5 ,6 ,7 ]
Chen, Po-Ku [1 ,2 ,3 ]
Chang, Shih-Hsin [1 ,2 ,8 ]
Chen, Der-Yuan [1 ,2 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Rheumatol & Immunol Ctr, Taichung, Taiwan
[2] China Med Univ, Coll Med, Taichung, Taiwan
[3] China Med Univ Hosp, Rheumatol & Immunol Ctr, Translat Med Lab, Taichung, Taiwan
[4] Natl Appl Res Labs, Taiwan Instrument Res Inst, Organ On A Chip Fabricat & Verificat Div, Hsinchu, Taiwan
[5] Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan
[6] Natl Cheng Kung Univ Hosp, Ctr Cell Therapy, Tainan, Taiwan
[7] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan
[8] Natl Chung Hsing Univ, Translat Med & Rong Hsing Res Ctr Translat Med, Taichung, Taiwan
[9] Chung Shan Med Univ, Inst Med, Taichung, Taiwan
关键词
remnant cholesterol (RC); low-density lipoprotein (LDL); prediction; cardiovascular events (CVE); rheumatoid arthritis (RA); DENSITY-LIPOPROTEIN CHOLESTEROL; TRIGLYCERIDE-RICH LIPOPROTEINS; LDL-CHOLESTEROL; RISK; DISEASE; ATHEROSCLEROSIS; INFLAMMATION; METAANALYSIS; TOFACITINIB; SOCIETY;
D O I
10.3389/fcvm.2024.1449219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) remains inadequately defined. Consequently, this study aims to evaluate the predictive value of remnant cholesterol (RC) for assessing CVD risk in RA patients. Methods Plasma RC levels were measured in 114 RA patients and 41 healthy controls, calculated as total cholesterol minus HDL-C and LDL-C. These levels were further analyzed using 1H-NMR lipid/metabolomics. Meanwhile, the 28-joint Disease Activity Score (DAS28) assessed RA activity. Results RC levels were significantly elevated in RA patients (19.0 mg/dl, p < 0.001) compared to healthy controls (14.5 mg/dl). Furthermore, RC levels were significantly elevated at 37.4 mg/dl in patients who experienced cardiovascular event (CVE) compared to 17.4 mg/dl in those without CVE (p < 0.001). To enhance the precision and reliability of RC measurements, RC concentrations were further validated using 1H-NMR spectroscopy. Additionally, a positive correlation was observed between RC levels and DAS28. Multivariate analysis identified RC as a significant predictor of CVE (odds ratio = 1.82, p = 0.013). ROC curve analysis revealed superior predictive capability of RC for CVE (AUC = 0.919, p < 0.001) compared to LDL-C (AUC = 0.669, p = 0.018), with a high sensitivity of 94.7% and a specificity of 82.1%. Conclusion Elevated RC levels demonstrate greater accuracy in predicting CVE occurrence in RA patients compared to traditional measures such as LDL-C. These findings suggest that elevated RC levels may serve as a novel predictor for occurrence of CVE in RA patients, facilitating early intervention strategies based on the risk stratification.
引用
收藏
页数:10
相关论文
共 53 条
[1]  
Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
[2]   Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies [J].
Avina-Zubieta, Juan Antonio ;
Thomas, Jamie ;
Sadatsafavi, Mohsen ;
Lehman, Allen J. ;
Lacaille, Diane .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (09) :1524-1529
[3]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[4]   Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk [J].
Baratta, Francesco ;
Cocomello, Nicholas ;
Coronati, Mattia ;
Ferro, Domenico ;
Pastori, Daniele ;
Angelico, Francesco ;
Ben, Maria Del .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
[5]   Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Boren, Jan ;
Chapman, M. John ;
Krauss, Ronald M. ;
Packard, Chris J. ;
Bentzon, Jacob F. ;
Binder, Christoph J. ;
Daemen, Mat J. ;
Demer, Linda L. ;
Hegele, Robert A. ;
Nicholls, Stephen J. ;
Nordestgaard, Brge G. ;
Watts, Gerald F. ;
Bruckert, Eric ;
Fazio, Sergio ;
Ference, Brian A. ;
Graham, Ian ;
Horton, Jay D. ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Masana, Luis ;
Pasterkamp, Gerard ;
Raal, Frederick J. ;
Ray, Kausik K. ;
Schunkert, Heribert ;
Taskinen, Marja-Riitta ;
van de Sluis, Bart ;
Wiklund, Olov ;
Tokgozoglu, Lale ;
Catapano, Alberico L. ;
Ginsberg, Henry N. .
EUROPEAN HEART JOURNAL, 2020, 41 (24) :2313-+
[6]   Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease [J].
Castaner, Olga ;
Pinto, Xavier ;
Subirana, Isaac ;
Amor, Antonio J. ;
Ros, Emilio ;
Hernaez, Alvaro ;
Angel Martinez-Gonzalez, Miguel ;
Corella, Dolores ;
Salas-Salvado, Jordi ;
Estruch, Ramon ;
Lapetra, Jose ;
Gomez-Gracia, Enrique ;
Alonso-Gomez, Angel M. ;
Fiol, Miquel ;
Serra-Majem, Lluis ;
Corbella, Emili ;
Benaiges, David ;
Sorli, Jose V. ;
Ruiz-Canela, Miguel ;
Babio, Nancy ;
Sierra, Lucas Tojal ;
Ortega, Emilio ;
Fito, Montserrat .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (23) :2712-2724
[7]  
Chang CK, 2023, CLIN EXP RHEUMATOL, V41, P1120, DOI 10.55563/clinexprheumatol/int08c
[8]   Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management [J].
Chapman, M. John ;
Ginsberg, Henry N. ;
Amarenco, Pierre ;
Andreotti, Felicita ;
Boren, Jan ;
Catapano, Alberico L. ;
Descamps, Olivier S. ;
Fisher, Edward ;
Kovanen, Petri T. ;
Kuivenhoven, Jan Albert ;
Lesnik, Philippe ;
Masana, Luis ;
Nordestgaard, Borge G. ;
Ray, Kausik K. ;
Reiner, Zeljko ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Tybjaerg-Hansen, Anne ;
Watts, Gerald F. .
EUROPEAN HEART JOURNAL, 2011, 32 (11) :1345-1361
[9]   Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance [J].
Charles-Schoeman, Christina ;
Buch, Maya H. ;
Dougados, Maxime ;
Bhatt, Deepak L. ;
Giles, Jon T. ;
Ytterberg, Steven R. ;
Koch, Gary G. ;
Vranic, Ivana ;
Wu, Joseph ;
Wang, Cunshan ;
Kwok, Kenneth ;
Menon, Sujatha ;
Rivas, Jose L. ;
Yndestad, Arne ;
Connell, Carol A. ;
Szekanecz, Zoltan .
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) :119-129
[10]   Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist [J].
Charles-Schoeman, Christina ;
Gonzalez-Gay, Miguel A. ;
Kaplan, Irina ;
Boy, Mary ;
Geier, Jamie ;
Luo, Zhen ;
Zuckerman, Andrea ;
Riese, Richard .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (01) :71-80